Correction: Result of AGM

Arix Bioscience plc

Correction: Results of Annual General Meeting

With correction to Table of Resolutions – Numbers 02 and 03.

LONDON, 03 June 2019: Arix Bioscience plc (“Arix”, LSE: ARIX) a global venture capital company focused on investing and building breakthrough biotech companies, announces that its Annual General Meeting (the "Meeting") was held on Monday, 3 June 2019 at 10.30am (BST). At the Meeting, the ordinary and special resolutions set out in the Notice of the Annual General Meeting dated 2 May 2019 (the "Notice of AGM"), were proposed and voted on by way of a poll.

Full details of the poll results are set out below and will also be available on the Company's website www.arixbioscience.com.

No	RESOLUTION	VOTES FOR	%	VOTES AGAINST	%	TOTAL VOTES	% of ISC VOTED	VOTES WITHHELD
01	To receive the Directors' report and the accounts for the Company for the year ended 31 December 2018	79,740,015	100.00	0	0.00	79,740,015	58.86%	3,894
02	To approve the Directors' Remuneration Policy	40,079,954	50.26	39,658,365	49.74	79,738,319	58.86%	5,590
03	To approve the Directors' Remuneration Report for the year ended 31 December 2018	23,179,050	32.41	48,338,181	67.59	71,517,231	52.79%	8,226,678
04	To re-elect Jonathan Peacock as a Director	75,716,711	94.95	4,025,628	5.05	79,742,339	58.86%	1,570
05	To re-elect Dr Franz Humer as a Director	74,175,937	93.02	5,566,402	6.98	79,742,339	58.86%	1,570
06	To re-elect Professor Trevor Jones as a Director	77,691,164	97.43	2,050,547	2.57	79,741,711	58.86%	2,198
07	To re-elect Giles Kerr as a Director	79,739,711	100.00	2,628	0.00	79,742,339	58.86%	1,570
08	To re-elect Dr Joseph Anderson as a Director	79,741,711	100.00	628	0.00	79,742,339	58.86%	1,570
09	To re-elect James Rawlingson as a Director	79,741,711	100.00	628	0.00	79,742,339	58.86%	1,570
10	To elect Art Pappas as a Director	76,266,164	95.64	3,476,175	4.36	79,742,339	58.86%	1,570
11	To elect Mark Breuer as a Director	79,741,711	100.00	0	0.00	79,741,711	58.86%	2,198
12	To re-appoint PwC LLP as auditors of the Company	72,224,733	90.57	7,524,156	9.43	79,748,889	58.87%	4,020
13	To authorise the Audit & Risk Committee of the Company to fix the remuneration of the auditors	78,313,875	98.21	1,426,485	1.79	79,740,360	58.86%	3,549
14	To authorise the Directors to allot shares	73,634,398	92.34	6,105,491	7.66	79,739,889	58.86%	4,020
15	To authorise the Directors to disapply statutory pre- emption rights in respect of 5% of the Company's issued share capital*	70,676,320	88.63	9,063,088	11.37	79,739,408	58.86%	4,501
16	To authorise the Directors to disapply statutory pre- emption rights in respect of an additional 5% of the Company's issued share capital*	71,033,320	89.08	8,706,088	10.92	79,739,408	58.86%	4,501
17	To authorise the Company to buy back shares*	79,736,396	99.99	5,063	0.01	79,741,459	58.86%	2,450
18	To authorise the Directors to call a general meeting other than an annual general meeting on not less than  14 clear days' notice*	79,739,242	100.00	2,250	0.00	79,741,492	58.86%	2,417

* Special resolution

In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed at www.hemscott.com/nsm.do

The Board is pleased that all resolutions at the meeting were passed other than the resolution to approve last year’s Directors’ Remuneration Report, Resolution 3. Over the next six months we shall engage with those shareholders we can identify who did not support this resolution to fully understand their concerns. Engagement will also take place with the small number of shareholders who did not support the resolution to approve the new Directors’ Remuneration Policy, which was passed but with a significant minority of votes against.

Since being set up in 2016, the Arix portfolio has grown and developed with 17 investments to date and four IPOs of portfolio companies in the past year. Multiple clinical milestones are expected over the next 12 months and the Company looks forward to reporting on continued progress throughout the year.

ENDS

Enquiries

For more information on Arix, please contact:

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

[phone]

[e-mail]

Optimum Strategic Communications

Mary Clark, Supriya Mathur

T: [phone]

[e-mail]

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

www.arixbioscience.com